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961Although 75% of patients in the AT group yielded
macroscopic thrombus material, the associated
microvascular obstruction assessed by magnetic
resonance imaging within 4 days was not different
from that of the control. The investigators conclude
that adjunctive AT does not lead to an improvement
of myocardial reperfusion and infarct size in patients
with NSTEMI. This conclusion, however, is arguable
because an important confounding factor was left out
from the analysis, namely the time from symptom
onset to PCI.
In the report from Thiele et al. (1), the time from
symptom onset to PCI was extended to 72 h, much
longer than the time limit used in previous AT trials
(<12 h in most AT trials in STEMI, and <24 h in the
earliest trial proving feasibility of AT in NSTEMI [2]).
The duration from symptom onset to PCI is associated
with the change in composition of thrombus material
(3). As thrombi “age,” the proportion of fresh throm-
botic material decreases whereas organized material
increases. Therefore, the effectiveness of AT in
restoring brisk coronary ﬂow will be reduced if done
late. In addition, irreversible injury also progresses in
the jeopardized, but salvageable, myocardium as
critical ischemia continues. This timing difference in
the effect of AT on myocardial reperfusion in STEMI
patients has been shown in previous studies (4,5). In
our previous study, the beneﬁt of AT is most signiﬁ-
cant in STEMI patients treated within 4 to 8 h after
symptom onset, compared with patients treated
within 0 to 4 h or 8 to 12 h. It is possible that within
4 h from onset the thrombi are so soft that they may
respond similarly to either conventional PCI or AT. On
the other hand, when AT was done later than 8 h from
onset, the thrombi are too organized to be removed
completely. In addition, as there is minimal myocar-
dium left to be salvaged late in the course, the beneﬁt
of AT will be mitigated. The changes in thrombus
composition and loss of salvageable myocardium as
time lapsed may thus result in an optimal “time
window” for AT to be effective. We believe, therefore,
the timing of AT after symptom onset should be
considered and analyzed accordingly in all future AT
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Timing Should Be ConsideredWe thank Dr. Hung and colleagues for their consid-
erations on timing of thrombectomy. In the TATORT-
NSTEMI (Thrombus Aspiration in Thrombus
Containing Culprit Lesions in Non-ST-Elevation
Myocardial Infarction) trial, the inclusion criterion
was indeed last symptoms <72 h, which is longer than
in previous ST-segment elevation myocardial infarc-
tion (STEMI) trials in which primary PCI is usually
performed <12 h after symptom onset, although the
recent TAPAS trial (Thrombus Aspiration during
Percutaneous coronary intervention in Acute
myocardial infarction Study) had a 24-h inclusion
criterion (1,2). However, in non-STEMI (NSTEMI), it is
usually difﬁcult to deﬁne the exact symptom onset
and also the last symptom occurrence because
symptoms are often stuttering. Therefore, the inclu-
sion criterion of last symptoms has been chosen in
multiple previous NSTEMI trials ranging from 24 to
72 h (3). Although the 72 h inclusion criterion in the
TATORT-NSTEMI trial was in the upper range in
comparison to other NSTEMI trials, the time from
last symptoms to angiography (TATORT-NSTEMI:
10.5 h thrombectomy vs. 10.0 h control) was similar
to previous trials ranging from 8 to 10 h in a timing
trial (3) and even shorter in comparison to another
trial with approximately 30 h until invasive angiog-
raphy (4).
Thrombus age may play a role on thrombec-
tomy success in STEMI patients. Currently, there is
conﬂicting evidence that aspiration thrombectomy
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962may be beneﬁcial in STEMI patients presenting
early. In the INFUSE-AMI trial including only ante-
rior STEMI patients presenting <4 h after symptom
onset, there was no beneﬁt of thrombectomy on
infarct size or any other marker of reperfusion
success (5). No data are available for NSTEMI
showing a relation of symptom onset on thrombus
age, which is also important in the light of
different thrombus composition in NSTEMI versus
STEMI. In a sensitivity analysis of the TATORT-
NSTEMI trial, there was no difference in the
primary endpoint of microvascular obstruction
for patients presenting with last symptoms <4 h
versus >4 h, supporting the overall results of
the trial.*Holger Thiele, MD
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